生长抑素受体2、3、5在乳腺癌组织中的表达及意义

Expressions of somatostatin receptor 2,3,5 in human breast cancer and their significance

目的检测乳腺癌组织中生长抑素受体(SSTR)2、3、5表达及分布情况,探讨SSTR2、3、5在乳腺癌阳性表达重要性及临床意义。方法以女性乳腺癌及乳腺良性病变为研究对象,并将其分为乳腺癌组、转移淋巴结组、癌旁组、乳腺良性病变组及正常乳腺对照组,采用免疫组化S-P法检测各组中SSTR2、3、5的分布及表达情况。结果SSTR2在乳腺癌组、转移淋巴结组、癌旁组、乳腺良性病变组和正常乳腺组织对照组中阳性表达率分别为52.0%、56.8%、14.0%、22.2%和16.7%;SSTR3分别为64.0%、62.2%、18.0%、33.3%和22.2%;SSTR5分别为60.0%、59.5%、14.0%、27.8%和11.1%。经统计学分析,SSTR2、3、5在乳腺癌组和转移淋巴结组与正常乳腺对照组比较差异有统计学意义(P<0.05);癌旁组和乳腺良性病变组与正常乳腺对照组比较,差异无统计学意义(P>0.05)。结论SSTR2、3、5在乳腺癌组和转移淋巴结组中呈高表达,而癌旁组、乳腺良性病变组和正常乳腺组织呈低表达,说明SSTR2、3、5表达的改变与乳腺癌发生和发展密切相关,这给临床上应用生长抑素治疗乳腺癌提供了理论依据,同时SSTR2、3、5有可能成为乳腺癌预后的一项重要的保护性指标。

Objective To study the expressions and distributions of somatostatin receptor （SSTR） 2,3,5 in human breast cancer, and investigate theirs clinical significance. Methods Female breast cancer and breast benign lesion were included in this study. It was divided into five groups ： breast cancer group, metastatic lymph node group, para-cancerous group, the benign lesion group and the normal control group. The distributions and expressions of SSTR 2,3,5 were detected in all the five groups by immunohistochemistrical examination （SP method）. Results The positive expressions of SSTR2 were 52.0%, 56.8%, 14. 0%, 22.2% and 16.7% in breast cancer group, metastatic lymph node group,para-cancerous group,the benign lesion group and the normal control group respectively ;the positive expressions of SSTR3 were 64.0% ,62.2% ,18.0% ,33.3% and 22.2% ;the positive expressions of SSTR5 were 60. 0% ,59.5%, 14.0% ,27.8% and 11.1%. Compared to the normal control group ,the positive expressions of SSTR 2,3,5 were significantly different in breast cancer group and metastatic lymph node group （ P 〈 0.05 ）. There was no significant difference in para-cancerous group and benign lesion group as compared to the normal control group （P 〉 0.05 ）. Condusions The positive expressions of SSTR 2,3,5 in breast cancer and its metastatic lymph nodes are higher than those in other tissues. It shows that the change of SSTR in breast cancer is closely redlated to the genesis and development of breast cancer. And it provids the theoretical basis to treat breast cancer with somatostatin （SST） in clinics. SSTR 2,3,5 may be the protective factors in breast cancer development.